Finasteride Tablet, Film Coated
Product Images NDC 71610-515

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 71610-515). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 5 mg (71610 0515 60)

This seems to be a label of a medication package. It contains information about the drug's National Drug Code (NDC), container specifications, lot number, expiration date, and batch number. The package also advises to keep the medication out of the reach of children.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Mm1 (Mm1)

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Mm2)

The text is describing a figure showing a symptom score in a long-term efficacy and safety study for a placebo and a drug called Finasteride. The figure shows the mean change from baseline and 1 standard error for each year of the study, which appears to have lasted for four years. There are also numbers corresponding to the baseline and each year of the study for both groups.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Mm3)

The text is a chart showing the percentage of patients having surgery for BPH, including TURP after taking Finasteride and Placebo for different time frames. The chart demonstrates that fewer patients who took Finasteride had surgery over time compared to those who took Placebo.*

FDA Label Image

Figure 3 Percent Of Patients Developing Acute Urinary Retention (spontaneous And Precipitated) (Mm4)

FDA Label Image

Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Mm5)

This is a chart (Figure 4) that depicts the prostate volume changes over a 4 year period in a long-term efficacy and safety study. The chart demonstrates the mean percent change from baseline in prostate volume, comparing a placebo group and a group that was administered Finasteride over the 4-year study. It shows the number of participants, events, and individuals at risk each year.*

FDA Label Image

Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Mm6)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.